clinical trial

[Isarna Therapeutics] Isarna Therapeutics announced the enrollment of the first patient in the BETTER Study, a parallel, two-segment Phase IIa clinical study to evaluate Isarna’s lead candidate ISTH0036 in patients with wet age-related macular degeneration (AMD) and diabetic macular edema (DME).

[InteRNA Technologies] InteRNA Technologies announced it received Investigational New Drug clearance from the US FDA for the company’s Phase I clinical trial evaluating lead miRNA candidate, INT-1B3, in patients with advanced solid tumors.

[Todos Medical, Ltd.] Todos Medical, Ltd. together with its 3CL biology-focused joint venture partner NLC Pharma, announced that all 31 patients enrolled to date in Tollovir® Phase II clinical trial in hospitalized COVID-19 patients completed study participation.

[Scientific Reports] The association between pulmonary sequelae and markers of disease severity, as well as pro-fibrotic mediators, were studied in 108 patients 3 months after hospital admission for COVID-19.

[Oncotelic Therapeutics, Inc.] Oncotelic Therapeutics, Inc. announced that it has submitted clinical study protocol to the US FDA for the initiation of a Phase II Trial for OT-101, the company’s TGF-β inhibitor, in combination with Anti-PD-1 as a treatment for patients with malignant pleural mesothelioma.

[AgeX Therapeutics, Inc.] AgeX Therapeutics, Inc. announced that ImStem Biotechnology, Inc., a biopharmaceutical company developing human ESC-derived mesenchymal stem cells, has dosed the first US multiple sclerosis patient with ImStem’s lead investigational drug candidate IMS001.